Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Mar;21(1):50-6.
doi: 10.4104/pcrj.2011.00090.

Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control

Roland A Riemersma  1 , Dirkje Postma, Thys van der Molen
Affiliations
Randomized Controlled Trial

Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control

Roland A Riemersma et al. Prim Care Respir J. 2012 Mar.

Abstract

Background: The management of asthma has changed since the introduction of budesonide/formoterol (Symbicort®) as both maintenance and reliever therapy (SMART). SMART and its effects on bronchial hyperresponsiveness (BHR) have not been studied in primary care.

Aims: To compare the effects of SMART and guideline-driven usual care (UC) on BHR and clinical asthma severity in primary care practice.

Methods: Patients with mild-to-moderate stable asthma were randomised to receive SMART treatment (n=54) (budesonide/formoterol 80/4.5 μg Turbuhaler®, two puffs once daily and extra inhalations as needed) or UC treatment (n=48) for 12 months. Diary data, Asthma Control Questionnaire scores, forced expiratory volume in 1 second (FEV1), and peak expiratory flow (PEF) measurements were collected during run-in and after 1, 3, 6, and 12 months of treatment. BHR, measured as the dose of histamine provoking a fall in FEV1 of 20% (PD20-histamine), was determined at randomisation and after 12 months.

Results: One hundred and two patients with asthma participated in the study. The change in PD20-histamine during the study was not significantly different between the SMART and UC groups (p=0.26). The mean inhaled corticosteroid (ICS) dose was 326 μg beclomethasone dipropionate (BDP) equivalents/day (95% CI 254 to 399) with SMART, which was significantly lower (p<0.0001) than the mean ICS dose with UC treatment (798 μg BDP equivalents/day (95% CI 721 to 875). Morning and evening PEF values increased significantly with SMART treatment compared with UC; FEV1, symptoms and asthma control did not differ.

Conclusions: Despite a 59% lower dose of ICS, BHR and other clinical outcomes remained stable during SMART treatment while PEF values improved.

Trial registration: ClinicalTrials.gov NCT00235911.

PubMed Disclaimer

Conflict of interest statement

RAR has received a research grant from AstraZeneca (AZ); and speaking fees, consulting fees, and reimbursement for attending conferences from AZ, GlaxoSmithKline (GSK), Boehringer, and MSD. DP has received a research grant from AZ; speaking fees, consulting fees, and reimbursement for attending conferences from AZ, GSK, MSD, Novartis, and Nycomed; funding for research from AZ, GSK, and Nycomed; travel to the ERS or ATS partially funded by AZ, GSK, Chiesi, and Nycomed; and she has been consultant to AZ, Boehringer Ingelheim, Chiesi, GSK, Nycomed, and TEVA. TvdM has received research grants from AZ, Nicomed, and MSD; speaking fees, consulting fees, and reimbursement for attending conferences from AZ and GSK; and has been consultant to AZ, MSD, Nicomed, and Novartis.

Figures

Figure 1
Figure 1. Study flow chart, V = visit, T = telephone contact
Figure 2
Figure 2. Enrolment of patients and completion of the study
Figure 3
Figure 3. Comparison of clinical characteristics of the current study with other SMART studies at baseline
Figure 4
Figure 4. ICS dose in μg BDP equivalents at baseline and after 1, 3, 6 and 12 months of treatment
See this image and copyright information in PMC

Comment in

References

    1. Global Initiative for Asthma (GINA). Global strategy for Asthma Management and Prevention (updated 2004). NIH Publication No. 02–3659. Bethesda, MD: National Institutes of Health, 2004.
    1. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) Study. Eur Respir J 2000;16:802–7. http://dx.doi.org/10.1183/09031936.00.16580200 - PubMed
    1. Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of patients with asthma on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006;6:13. http://dx.doi.org/10.1186/1471-2466-6-13 - PMC - PubMed
    1. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1412–18. http://dx.doi.org/10.1056/NEJM199711133372001 - PubMed
    1. O'Byrne PM, Barnes PJ, Rodriguez Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392–7. - PubMed

Publication types

MeSH terms

Associated data